Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 734 results for diabet*

  1. VA ECMO for severe acute heart failure in adults (IPG807)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  2. Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537)

    Evidence-based recommendations on insertion of a subretinal prosthesis system for retinitis pigmentosa. This involves performing a vitrectomy and implanting a microchip underneath the macula using a transscleral, then subretinal approach.

  3. Lipids disorders: FH assessment (30 years and over) (IND204)

    This indicator covers the percentage of people aged 30 years and older with a total cholesterol concentration greater than 9.0 mmol/l that are assessed against the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM183

  4. Lipids disorders: FH assessment (29 years and under) (IND203)

    This indicator covers the percentage of people aged 29 years and under, with a total cholesterol concentration greater than 7.5 mmol/l that are assessed against the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM182

  5. Hypothyroidism: annual thyroid function test (IND139)

    This indicator covers the percentage of patients with hypothyroidism, on the register, with thyroid function tests recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM100

  6. Hypothyroidism: register (IND138)

    This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.

  7. Lipid disorders: FH assessment and diagnosis (new readings) (IND261)

    This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245

  8. Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)

    This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244

  9. Use of routinely collected real-world data to examine the effectiveness and cost effectiveness of continuous glucose monitoring: Based on routinely collected real-world data, what is the effectiveness and cost effectiveness of CGM devices to improve glycaemic control?

    monitoring in adults with type 1 diabetes. Source guidance details Comes from guidance Type 1 diabetes in adults: diagnosis...

  10. When is it safe to stop contact casting in the treatment of acute Charcot arthropathy?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

  11. Which risk stratification tools can be used to predict the likelihood of Charcot arthropathy?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date

  12. How do financial factors (including incentives, pricing and taxation of food and incentives, and pricing for physical activity opportunities) affect food and physical activity choices?

    None. Source guidance details Comes from guidance Type 2 diabetes prevention: population and community-level interventions Number

  13. What is the effectiveness of different footwear, insoles and orthoses in the prevention of foot problems?

    applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date